WallStSmart
MESO

Mesoblast Ltd

NASDAQ: MESO · HEALTHCARE · BIOTECHNOLOGY

$15.55
+2.17% today

Updated 2026-04-29

Market cap
$2.01B
P/E ratio
P/S ratio
30.75x
EPS (TTM)
$-0.74
Dividend yield
52W range
$10 – $22
Volume
0.3M

Mesoblast Ltd (MESO) Earnings

Quarterly earnings history, analyst estimates, and stock price reaction.

EPS beat streak
7 of 8
Last 8 quarters
Avg EPS surprise
+77.6%
Last 4 quarters
Revenue YoY growth
Most recent quarter
EPS YoY growth
+75.0%
Most recent quarter

When is the next earnings report?

Reporting date
June 30, 2024
Consensus EPS estimate
$-0.36
Fiscal period ending
2024-06-30

Earnings surprise history (last 12 quarters)

Beat estimate Missed estimate

Quarterly EPS and revenue trend

Quarterly revenue EPS (diluted)

How the stock reacts to earnings

Avg 1-day reaction
-3.5%
Last 2 reports
Positive reaction rate
50%
1 of 2 quarters
Largest single-day move
-14.2%
2025-08-28
Report dateEPS actualSurpriseClose beforeClose after1-day reaction
2025-11-26$-0.07+30.0%$16.06$17.23+7.3%
2025-08-28$-0.04+90.0%$16.12$13.83-14.2%

Quarterly earnings history

Fiscal quarter endingEPS estimateEPS actualSurpriseRevenueYoY revenue
2025-12-31$-0.07
2025-09-30$-0.10$-0.07+30.0%
2025-06-30$-0.40$-0.04+90.0%$7.02M+458.6%
2025-03-31$-0.14$0.00+100.0%$7.02M+458.6%
2024-12-31$-0.41$-0.04+90.2%$1.58M-6.8%
2024-09-30$-0.31$-0.28+9.7%$1.58M-6.8%
2024-06-30$-0.36$1.26M-41.2%
2024-03-31$-0.11$0.00+100.0%$1.26M
2023-12-31$-0.40$0.00+100.0%$1.69M
2023-09-30$-0.12$-0.13-6.8%$1.69M
2023-06-30$-0.15$-0.14+6.7%$2.14M

Frequently asked questions

When does Mesoblast Ltd report next earnings?
Mesoblast Ltd (MESO) is scheduled to report earnings on June 30, 2024. The consensus EPS estimate is $-0.36.
Has Mesoblast Ltd beaten earnings estimates?
Mesoblast Ltd has beaten Wall Street EPS estimates in 7 of its last 8 quarterly reports, with an average EPS surprise of +77.6% over the last 4 quarters.
How does MESO stock react to earnings?
MESO stock has moved an average of -3.5% in the trading day following earnings over its last 2 reports, with positive reactions in 50% of those quarters.